What's expected at ARVO 2025?

0 Phase 3 trials are estimated to complete within the conference window. Focus areas: Ophthalmology.

How is this list generated?

Phase 3 trials with primary completion dates in the 4 months leading up to + 1 month after the conference, sourced from ClinicalTrials.gov. Not every trial will present at the conference — but most pivotal data in the area typically debuts within this window.

ARVO 2025 — Association for Research in Vision and Ophthalmology Annual Meeting

Largest annual ophthalmology research conference. Key venue for AMD, DR, dry eye, gene therapy + cell therapy in retinal disease.

May 4-8 Various (Seattle, Denver, Vancouver, Salt Lake City) Ophthalmology Archive

Phase 3 watch list (0 trials in the ±2-month window)

Trials with primary completion in the months leading up to + just after the conference — the typical window for pivotal data presentations.

No Phase 3 trials with completion in this window.

Recent / nearby approvals in the area

No nearby approvals in the area.

Subscribe to conference alerts

Get every Phase 3 readout + approval in this therapeutic area:

Phase 3 readouts RSS
Recent approvals RSS
Build a custom filter

All ARVO years + other conferences
Full Phase 3 readout calendar
Upcoming PDUFA dates
CI briefs

ARVO 2025 — Association for Research in Vision and Ophthalmology Annual Meeting

Phase 3 watch list (0 trials in the ±2-month window)

Recent / nearby approvals in the area

Subscribe to conference alerts

Related